leadf
logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon Pharma enrolls first patient from the US for multinational Phase 2b/3 coronavirus study of Ifenprodil

The target is for 150 patients from all participating sites and so far, the firm has enrolled 26 since the study began on August 5 this year

Algernon Pharmaceuticals Inc. -
Algernon believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF), the drug repurposing firm, told investors it has enrolled its first patient from the US for its multinational Phase 2b/3 human study of Ifenprodil to treat coronavirus (COVID-19).

"We are very pleased to announce our first U.S. patient,” said Christopher J. Moreau, the chief executive of the Vancouver-based company said in a statement. "We have also had steady enrollment from one of our International sites and as a result, we expect to reach 25% of our total target shortly."

READ: Algernon says first patient dosed in Phase 2 study of Ifenprodil as a treatment in idiopathic pulmonary fibrosis and chronic cough

That target is 150 patients from all participating sites and so far, the firm has enrolled 26 since the study began on August 5 this year.

The trial will begin as a Phase 2b study of 150 patients and will move directly into a Phase 3 trial if preliminary data is positive. The data from the Phase 2b will determine the number of patients needed to reach statistical significance in the Phase 3 study.

Algernon believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively.

The latter can result in the so-called cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in coronavirus (COVID-19) infected patients.

Contact the author at giles@proactiveinvestors.com

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.31 CAD

CSE:AGN
Market: CSE
Market Cap: $34.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll...

Algernon Pharmaceutical (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has now enrolled a third of their patients in the Phase 2B/3 study of their repurposed drug Ifenprodil. Moreau discusses hitting that mark and also...

2 weeks, 4 days ago

2 min read